CEO’s Insider Buy Signals Confidence in Lipocine’s Oral Drug Strategy
CEO Patel’s recent purchase of 25,000 Lipocine shares at $2.02 shows confidence in its oral‑delivery platform, yet highlights the company’s volatility, pipeline risks and need to prove market value.
4 minutes to read